Twist launches new biotech firm

By The Science Advisory Board staff writers

November 15, 2021 -- Twist Bioscience has launched a new biotechnology firm, Revelar Biotherapeutics, to develop and market an antibody discovered by Twist that neutralizes SARS-CoV-2.

Twist expects Revelar to begin clinical studies of the antibody in 2022. It will also license up to five additional antibodies developed by Twist over the next four years. Twist may receive milestone payments from Revelar of more than $100 million for development, regulatory, and commercial milestones, it said.


Copyright © 2021 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.